Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

March 12, 2024

https://www.globenewswire.com/news-release/2024/03/12/2844522/0/en/Allogene-Therapeutics-and-Arbor-Biotechnologies-Announce-Global-Gene-Editing-Licensing-Agreement-to-Support-Advancement-of-Next-Generation-Allogeneic-CAR-T-Platform-in-Autoimmune-D.html

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, and Arbor Biotechnologies, Inc. (“Arbor”), a biotechnology company discovering and developing the next generation of genetic medicines, today announced a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune disease (AID).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.